Sign In
Buy VRTX
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
08:32am, Thursday, 25'th Jan 2024
From CRISPR gene editing to modify ideal agricultural traits, synthetic biology to promote eco-friendly engineering, or even that relating to biofuels, the field of biotechnology, also known as biotec
PBYI or VRTX: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 24'th Jan 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value in
Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?
10:31am, Wednesday, 24'th Jan 2024
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
06:56pm, Tuesday, 23'rd Jan 2024
Vertex Pharmaceuticals (VRTX) reachead $439.70 at the closing of the latest trading day, reflecting a -0.09% change compared to its last close.
2 gene editing stocks to keep on your 2024 watchlist
08:23am, Tuesday, 23'rd Jan 2024
Gene therapy will get its share of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP CR
3 Must-Buy Healthcare Stocks for a Healthy 2024
05:27pm, Monday, 22'nd Jan 2024
Healthcare stocks remain a focal point for investors seeking stability and growth. The convergence of technology and an increased emphasis on global health has created an environment for ripe investme
3 Unstoppable Growth Stocks That Can Make You Richer in 2024
12:50pm, Saturday, 20'th Jan 2024
Amazon's profits are improving significantly, and generative AI is providing it with a major ongoing tailwind. MercadoLibre has tremendous growth prospects in Latin America.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
06:56pm, Wednesday, 17'th Jan 2024
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $433.76, signifying a -0.85% move from its prior day's close.
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
01:06pm, Wednesday, 17'th Jan 2024
This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
CRISPR-derived drug gets green light for second indication
03:29am, Wednesday, 17'th Jan 2024
The Food & Drug Administration has approved a second indication for a drug developed using a gene editing process called CRISPR. Casgevy, initially authorised in December for sickle cell disease trea
FDA Approves New CRISPR Gene-Editing Treatment
05:59pm, Tuesday, 16'th Jan 2024
The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusio
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
03:19pm, Tuesday, 16'th Jan 2024
The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a rare blood disorder requiring regular blood transfusions, in patients 1
My 3 Highest-Conviction Growth Stocks to Buy in 2024
10:13am, Sunday, 14'th Jan 2024
Amazon is well positioned to remain a leader in e-commerce and cloud services. Brookfield Renewable has almost sure-fire growth prospects with the rising demand for renewable energy.
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
09:00am, Sunday, 14'th Jan 2024
AI should provide a huge tailwind for Alphabet. MercadoLibre has major growth opportunities in Latin America's e-commerce and fintech markets.
3 Unstoppable Stocks to Buy in 2024
07:48am, Saturday, 13'th Jan 2024
Eli Lilly is growing by leaps and Zepbounds. Novo Nordisk is just getting warmed up after delivering a 53% gain last year.
